This company has been marked as potentially delisted and may not be actively trading. TF Financial (THRD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock THRD vs. RCUS, SNDX, AVDL, SYRE, PHVS, ZYME, CVAC, ARDX, CMRX, and CDMOShould you be buying TF Financial stock or one of its competitors? The main competitors of TF Financial include Arcus Biosciences (RCUS), Syndax Pharmaceuticals (SNDX), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Pharvaris (PHVS), Zymeworks (ZYME), CureVac (CVAC), Ardelyx (ARDX), Chimerix (CMRX), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical preparations" industry. TF Financial vs. Arcus Biosciences Syndax Pharmaceuticals Avadel Pharmaceuticals Spyre Therapeutics Pharvaris Zymeworks CureVac Ardelyx Chimerix Avid Bioservices TF Financial (NASDAQ:THRD) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations. Do analysts prefer THRD or RCUS? TF Financial presently has a consensus target price of $9.33, suggesting a potential upside of 80.18%. Arcus Biosciences has a consensus target price of $25.67, suggesting a potential upside of 183.77%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than TF Financial.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TF Financial 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91 Which has more volatility and risk, THRD or RCUS? TF Financial has a beta of 2.66, meaning that its share price is 166% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Which has higher earnings and valuation, THRD or RCUS? TF Financial has higher earnings, but lower revenue than Arcus Biosciences. TF Financial is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTF FinancialN/AN/A-$30.82M-$0.62-8.35Arcus Biosciences$141M6.79-$307M-$4.19-2.16 Does the MarketBeat Community believe in THRD or RCUS? Arcus Biosciences received 139 more outperform votes than TF Financial when rated by MarketBeat users. However, 65.59% of users gave TF Financial an outperform vote while only 65.57% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformTF FinancialOutperform Votes6165.59% Underperform Votes3234.41% Arcus BiosciencesOutperform Votes20065.57% Underperform Votes10534.43% Is THRD or RCUS more profitable? TF Financial has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. TF Financial's return on equity of -9.31% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets TF FinancialN/A -9.31% -9.03% Arcus Biosciences -102.66%-45.59%-22.38% Does the media favor THRD or RCUS? In the previous week, Arcus Biosciences had 3 more articles in the media than TF Financial. MarketBeat recorded 3 mentions for Arcus Biosciences and 0 mentions for TF Financial. Arcus Biosciences' average media sentiment score of 1.72 beat TF Financial's score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Overall Sentiment TF Financial Neutral Arcus Biosciences Very Positive Do insiders & institutionals have more ownership in THRD or RCUS? 94.0% of TF Financial shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 5.9% of TF Financial shares are held by insiders. Comparatively, 12.3% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryArcus Biosciences beats TF Financial on 10 of the 18 factors compared between the two stocks. Get TF Financial News Delivered to You Automatically Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THRD vs. The Competition Export to ExcelMetricTF FinancialPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$233.41M$6.46B$5.33B$8.31BDividend YieldN/A2.63%5.27%4.09%P/E Ratio-8.358.3626.7119.58Price / SalesN/A258.94395.60135.07Price / CashN/A65.8538.3234.62Price / Book0.786.416.764.50Net Income-$30.82M$143.73M$3.23B$248.40M TF Financial Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THRDTF Financial1.4339 of 5 stars$5.18-0.4%$9.33+80.2%-62.8%$233.41MN/A-8.35N/ARCUSArcus Biosciences3.5446 of 5 stars$8.52-3.2%$25.67+201.3%-44.4%$902.14M$141M-2.70500Positive NewsSNDXSyndax Pharmaceuticals3.796 of 5 stars$10.42-5.2%$35.91+244.6%-51.0%$896.61M$43.72M-2.87110Positive NewsAVDLAvadel Pharmaceuticals2.2666 of 5 stars$9.10-5.1%$19.43+113.5%-41.5%$879.32M$169.12M-11.5270Positive NewsSYRESpyre Therapeutics2.3257 of 5 stars$14.43-3.3%$53.40+270.1%-54.1%$869.78M$890,000.00-1.93100Positive NewsGap DownPHVSPharvaris1.27 of 5 stars$16.62-1.1%$41.67+150.7%-18.2%$869.06MN/A-5.9430ZYMEZymeworks3.3336 of 5 stars$11.77-2.1%$21.00+78.4%+32.5%$818.92M$93.38M-7.85460News CoverageAnalyst ForecastAnalyst RevisionCVACCureVac3.5808 of 5 stars$3.64+0.6%$14.00+284.6%+3.0%$816.59M$535.18M6.62880News CoverageEarnings ReportAnalyst RevisionGap DownARDXArdelyx4.3944 of 5 stars$3.39-4.0%$10.39+206.5%-46.6%$811.07M$361.71M-21.1990Insider TradeGap DownCMRXChimerix0.5741 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990CDMOAvid Bioservices0.8019 of 5 stars$12.50+0.1%$12.25-2.0%+41.5%$799.18M$139.91M-5.23320High Trading Volume Related Companies and Tools Related Companies Arcus Biosciences Competitors Syndax Pharmaceuticals Competitors Avadel Pharmaceuticals Competitors Spyre Therapeutics Competitors Pharvaris Competitors Zymeworks Competitors CureVac Competitors Ardelyx Competitors Chimerix Competitors Avid Bioservices Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THRD) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TF Financial Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share TF Financial With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy THRD Stock Free THRD Stock Alerts